EngineChem Life Science Space Radiation Medical Research Institute Collaborates with Inha University Aerospace Medical Science Research Institute

[Asia Economy Reporter Hyungsoo Park] On the 20th, Engchem Life Sciences' Space Radiation Pharmaceutical Research Institute announced that it signed a business agreement for research cooperation with Inha University’s Aerospace Medical Science Research Institute on the 16th.

Starting from this business agreement, plans are underway to promote joint research and related projects on aerospace pharmaceuticals involving private companies, university research institutions, and public organizations.

Engchem Life Sciences was finally selected in January for NASA’s space radiation therapeutic research project. Professor Cheryl Nickerson of Arizona State University (ASU), who conducted joint research, is one of the authorities who participated in NASA’s space shuttle mission in 2006 and has been studying human survival strategies against the increased toxicity of microorganisms in outer space.

Engchem Life Sciences is conducting development and research on space radiation and acute radiation syndrome prevention and treatment drugs not only with NASA but also with the U.S. National Institute of Allergy and Infectious Diseases (NIAID) under the National Institutes of Health (NIH), the U.S. Army’s Armed Forces Radiobiology Research Institute (AFRRI) under the Department of Defense (DoD), the Korea Institute of Radiological & Medical Sciences (KIRAMS), and the Korea Research Institute of Bioscience and Biotechnology (KRIBB).

Inha University’s Aerospace Medical Science Research Institute is the first aerospace medical science research institute established in Korea. It has led Korea’s aerospace development by conducting aerospace medical research related to sensory, vascular, and immune systems. The institute has established facilities such as a gravity load experiment device, microgravity simulation device, and sleep regulation experiment device.

Professor Kyuseong Kim, director of Inha University’s Aerospace Medical Science Research Institute, said, “Human tissues such as the vestibular system, nervous system, blood vessels, and muscles, which are specialized for Earth’s environment, are exposed to serious threats in outer space. Collaboration with Engchem Life Sciences’ Space Radiation Pharmaceutical Research Institute, which has been conducting global research for the development of space immune system-related therapeutics, can become a historic milestone leading the upcoming era of space flight.”

Director Gapjoo Park of the Space Radiation Pharmaceutical Research Institute explained, “Through the signing of this agreement, academic exchanges and research cooperation in various fields of aerospace biomedical science and space health translational research between the two institutions will be enhanced, raising the excellent capabilities of Korea’s aerospace medicine.” Director Gapjoo Park, nicknamed ‘Atom Park,’ has over 30 years of new drug and bio R&D experience at Seoul National University, Pohang University of Science and Technology, Brown University, Pfizer, and Pasteur Institute.

Chairman Kiyoung Son of Engchem Life Sciences emphasized, “Going forward, Engchem Life Sciences’ Space Radiation Pharmaceutical Research Institute will develop space radiation prevention and treatment drugs through joint research with Inha University’s Aerospace Medical Science Research Institute and U.S. institutions such as Harvard University, Arizona State University, UC Davis, and the University of Florida.”

This content was produced with the assistance of AI translation services.